FDC Ltd. — Earnings Release 2021

Nov 11, 2020

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

November 11, 2020

BSELimited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 531599 Symbol: FOC

Sub: Press Release

Dear Sir / Madam,

Please find attached herewith the Press Release issued in relation to the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter & half ...•. year ended so" September, 2020.

Kindly take the same on record.

Thanking you,

Yours truly

For FOClimited

VARSHARANI RAJARAM KATRE Digitally signed by VARSHARANI RAJARAM KATRE Date: 2020.11.11 11:57:42

Varsharani Katre Company Secretary F-8948 +05'30'

CORPORATEOFFICE	: 142·48, S. V. Road. Jogeshwari(W), Mumbai - 400 102. INDIATel.: +91-22-62917900/950/26780652/2653/2656• Fax:+91-22-26773462
	E-mail:fdc@fdcindia.com• Website:www.fdcindia.com
REGISTEREDOFFICE	: B-8, M.I.D.C.IndustrialArea, Waluj - 431 136, Dist. Aurangabad.INDIATel.: 0240-2554407/2554299/2554967• Fax:0240-2554299E-mail:waluJ@fdcindia.com• CIN : L24239MH1940PLC003176

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS FDe Limited reports Q2FY21 results

Mumbai, November 11,2020: FOC Limited (NSE: FOC, BSE: 531599, ISIN: INE258B01022) reported financia1s for the second quarter ending 30th Sep., 2020.

Q2'20-21	Q2'19-20	%YOYGrowth
37,139.44	34,611.85	7.30
		37.44
31.95		37.44
		42.19
		63.03
		64.01
	12,475.6911,428.688,808.125.15	9,076.9025.008,037.615,402.713.14

Consolidated Q2FY21 and HIFY21 FDC reported:

Rs.inlakhs	HI'20-21	Hl'19-20	%YOYGrowth
OperatingRevenues	67,957.41	68,963.78	-1.46
EBITDA	25,630.64	17,903.28	43.16
EBITDA%	35.28	24.99	43.16
PBT	23,564.91	15,846.85	48.70
PAT	17,980.15	11,024.63	63.09
EPS	10.52	6.41	64.12

Commenting on the results;

During these challenging times of Covid-19 the company has constantly focused on reducing cost, introducing new products and delivering more Export orders which have helped in increasing the sales and operating profit in the second quarter of this financial year. The Formulations and API exports have performed well during HI FY21. Our timely risk mitigation initiatives ensured smooth operations of our manufacturing network, thereby maintaining continuous supplies of drugs. In the meantime, we continue to focus on serving our patients and customers, ensuring safety of our employees and business continuity.

India Market:

Sale of branded formulations in India for Q2FY21 was Rs. 274.34 crores, a decline of 6.77 % over the same quarter last year. Overall sales in India markets accounted for 74.97% of total consolidated sales for the quarter. For the first half, sales were at Rs.507.60 crores, decline of 10.05% over the same period last year.

REGISTERED OFFICE

: 142-48, S. V. Road, Jogeshwari 0N), Mumbai - 400102. INDIA Tel.: +91-22-6291 7900/950/26780652/2653/2656 • Fax: +91-22-2677 3462 E-mail: fdc@fdcindia.com • Website: www.fdcindia.com

: 8-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA Tel.: 0240-2554407/2554299/2554967 • Fax: 0240-2554299 E-mail: waluj@fdcindia.com • CIN : L24239MH1940PLC003176

Foe Limited No.

FDC has believed in providing quality products at affordable prices. So, to fight Coronavirus and help the society, FDC has launched Favipiravir for the treatment of mild to moderate cases of Covid-19 and other related products in the Domestic market.

Export Formulations Market:

Formulation Sales in the Export market were Rs. 78.24 crores in Q2FY21, up by 122.01% over Q2 last year and accounted for 21.27 % of total consolidated sales. For first half sales were Rs. 137.50 crores, up by 42.72% over same period last year. The main contributor is the USA market, accounting to 70.55% of total Export Formulations Sales.

We have increased our stake in the SA entity (to 93%) for better control and management. This investment would help in taking timely decisions and improve our presence in the African countries.

Export API Market:

API Sales in the Export market were Rs. 13.85 crores in Q2FY21, up by 3.18% over Q2 last year and accounted for 3.76% of total consolidated sales. For the first half, sales were Rs. 29.13 crores, up by 18.27 % over first half last year. We are exploring newer avenues to increase the Export API sales in the coming year.

ABOUT FDC LTD

Established in 1940, with the dream of building a world class company and vision to make the nation self-reliant in healthcare. FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmic. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients CAPls) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Vema in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modem technology, empowering talent and expanding healthcare horizons for a better quality of life to millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forwardlooking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.